Loading…
Is There Enough Vaccine to Eradicate Measles? An Integrated Analysis of Measles-Containing Vaccine Supply and Demand
Responding to regional advancements in combating measles, the World Health Organization in May 2008 called for an assessment of the feasibility of measles eradication, including whether sufficient vaccine supply exists. Interviews with international health officials and vaccine-makers provided data...
Saved in:
Published in: | The Journal of infectious diseases 2011-07, Vol.204 (suppl_1), p.S62-S70 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c386t-1b3d1b11f64adac4dd44a86d4f59f034afc476c500aecfbb8cd8b2ee0163c193 |
---|---|
cites | |
container_end_page | S70 |
container_issue | suppl_1 |
container_start_page | S62 |
container_title | The Journal of infectious diseases |
container_volume | 204 |
creator | Smith, Graegar Michelson, Joshua Singh, Rohit Dabbagh, Alya Hoekstra, Edward van den Ent, Maya Mallya, Apoorva |
description | Responding to regional advancements in combating measles, the World Health Organization in May 2008 called for an assessment of the feasibility of measles eradication, including whether sufficient vaccine supply exists. Interviews with international health officials and vaccine-makers provided data for a detailed model of worldwide demand and supply for measles-containing vaccine (MCV). The study projected global MCV demand through 2025 with and without a global eradication goal. The study found that 5.2 billion MCV doses must be administered during 2010-2025 to maintain current measles programs, and 5.9 billion doses would likely be needed with a 2020 eradication goal; in the most intensive scenario, demand could increase to 7.5 billion doses. These volumes are within existing and planned MCV-manufacturing capacity, although there are risks. In some markets, capacity is concentrated: Supply-chain disruptions could reduce supply or increase prices. Mitigation strategies could include stockpiling, long-term contracts, and further coordination with manufacturers. |
doi_str_mv | 10.1093/infdis/jir130 |
format | article |
fullrecord | <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_872434879</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>41230446</jstor_id><oup_id>10.1093/infdis/jir130</oup_id><sourcerecordid>41230446</sourcerecordid><originalsourceid>FETCH-LOGICAL-c386t-1b3d1b11f64adac4dd44a86d4f59f034afc476c500aecfbb8cd8b2ee0163c193</originalsourceid><addsrcrecordid>eNqF0DtPwzAUBWALgWh5jIwgb7AE7Nh1kglVpUAlEAMVa-TY162r1A52MvTfkyrQlenoXn06w0HoipJ7Sgr2YJ3RNj5sbKCMHKExnbAsEYKyYzQmJE0TmhfFCJ3FuCGEcCayUzRKqRAipZMxahcRL9cQAM-d71Zr_CWVsg5w6_E8SG2VbAG_g4w1xEc8dXjhWliF_qv7S9a7aCP25o8kM-9aaZ11q0PVZ9c09Q5Lp_ETbPu4QCdG1hEuf_McLZ_ny9lr8vbxsphN3xLFctEmtGKaVpQawaWWimvNucyF5mZSGMK4NIpnQk0IkaBMVeVK51UKQKhgihbsHN0OtU3w3x3EttzaqKCupQPfxTLPUs54nu1lMkgVfIwBTNkEu5VhV1JS7mcuh5nLYebe3_w2d9UW9EH_7dqDuwH4rvm363qgm9j6cMCcpoxwLtgPCJCTYA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>872434879</pqid></control><display><type>article</type><title>Is There Enough Vaccine to Eradicate Measles? An Integrated Analysis of Measles-Containing Vaccine Supply and Demand</title><source>JSTOR Archival Journals and Primary Sources Collection</source><source>Oxford Journals Online</source><creator>Smith, Graegar ; Michelson, Joshua ; Singh, Rohit ; Dabbagh, Alya ; Hoekstra, Edward ; van den Ent, Maya ; Mallya, Apoorva</creator><creatorcontrib>Smith, Graegar ; Michelson, Joshua ; Singh, Rohit ; Dabbagh, Alya ; Hoekstra, Edward ; van den Ent, Maya ; Mallya, Apoorva</creatorcontrib><description>Responding to regional advancements in combating measles, the World Health Organization in May 2008 called for an assessment of the feasibility of measles eradication, including whether sufficient vaccine supply exists. Interviews with international health officials and vaccine-makers provided data for a detailed model of worldwide demand and supply for measles-containing vaccine (MCV). The study projected global MCV demand through 2025 with and without a global eradication goal. The study found that 5.2 billion MCV doses must be administered during 2010-2025 to maintain current measles programs, and 5.9 billion doses would likely be needed with a 2020 eradication goal; in the most intensive scenario, demand could increase to 7.5 billion doses. These volumes are within existing and planned MCV-manufacturing capacity, although there are risks. In some markets, capacity is concentrated: Supply-chain disruptions could reduce supply or increase prices. Mitigation strategies could include stockpiling, long-term contracts, and further coordination with manufacturers.</description><identifier>ISSN: 0022-1899</identifier><identifier>EISSN: 1537-6613</identifier><identifier>DOI: 10.1093/infdis/jir130</identifier><identifier>PMID: 21666215</identifier><language>eng</language><publisher>United States: Oxford University Press</publisher><subject>Child, Preschool ; Countries ; Developed Countries ; Developing Countries ; FEASIBILITY OF MEASLES ERADICATION ; Financial risk ; Forecasting ; Global Health ; Humans ; Immunization ; Infant ; Measels mumps rubella vaccine ; Measles ; Measles - prevention & control ; Measles Vaccine - economics ; Measles Vaccine - supply & distribution ; Measles vaccines ; Political campaigns ; Rubella ; Supply ; Vaccination ; Vaccination - economics</subject><ispartof>The Journal of infectious diseases, 2011-07, Vol.204 (suppl_1), p.S62-S70</ispartof><rights>Copyright © 2011 Oxford University Press on behalf of the Infectious Diseases Society of America</rights><rights>The Author 2011. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com 2011</rights><rights>The Author 2011. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c386t-1b3d1b11f64adac4dd44a86d4f59f034afc476c500aecfbb8cd8b2ee0163c193</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/41230446$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/41230446$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,58238,58471</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21666215$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Smith, Graegar</creatorcontrib><creatorcontrib>Michelson, Joshua</creatorcontrib><creatorcontrib>Singh, Rohit</creatorcontrib><creatorcontrib>Dabbagh, Alya</creatorcontrib><creatorcontrib>Hoekstra, Edward</creatorcontrib><creatorcontrib>van den Ent, Maya</creatorcontrib><creatorcontrib>Mallya, Apoorva</creatorcontrib><title>Is There Enough Vaccine to Eradicate Measles? An Integrated Analysis of Measles-Containing Vaccine Supply and Demand</title><title>The Journal of infectious diseases</title><addtitle>J Infect Dis</addtitle><description>Responding to regional advancements in combating measles, the World Health Organization in May 2008 called for an assessment of the feasibility of measles eradication, including whether sufficient vaccine supply exists. Interviews with international health officials and vaccine-makers provided data for a detailed model of worldwide demand and supply for measles-containing vaccine (MCV). The study projected global MCV demand through 2025 with and without a global eradication goal. The study found that 5.2 billion MCV doses must be administered during 2010-2025 to maintain current measles programs, and 5.9 billion doses would likely be needed with a 2020 eradication goal; in the most intensive scenario, demand could increase to 7.5 billion doses. These volumes are within existing and planned MCV-manufacturing capacity, although there are risks. In some markets, capacity is concentrated: Supply-chain disruptions could reduce supply or increase prices. Mitigation strategies could include stockpiling, long-term contracts, and further coordination with manufacturers.</description><subject>Child, Preschool</subject><subject>Countries</subject><subject>Developed Countries</subject><subject>Developing Countries</subject><subject>FEASIBILITY OF MEASLES ERADICATION</subject><subject>Financial risk</subject><subject>Forecasting</subject><subject>Global Health</subject><subject>Humans</subject><subject>Immunization</subject><subject>Infant</subject><subject>Measels mumps rubella vaccine</subject><subject>Measles</subject><subject>Measles - prevention & control</subject><subject>Measles Vaccine - economics</subject><subject>Measles Vaccine - supply & distribution</subject><subject>Measles vaccines</subject><subject>Political campaigns</subject><subject>Rubella</subject><subject>Supply</subject><subject>Vaccination</subject><subject>Vaccination - economics</subject><issn>0022-1899</issn><issn>1537-6613</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNqF0DtPwzAUBWALgWh5jIwgb7AE7Nh1kglVpUAlEAMVa-TY162r1A52MvTfkyrQlenoXn06w0HoipJ7Sgr2YJ3RNj5sbKCMHKExnbAsEYKyYzQmJE0TmhfFCJ3FuCGEcCayUzRKqRAipZMxahcRL9cQAM-d71Zr_CWVsg5w6_E8SG2VbAG_g4w1xEc8dXjhWliF_qv7S9a7aCP25o8kM-9aaZ11q0PVZ9c09Q5Lp_ETbPu4QCdG1hEuf_McLZ_ny9lr8vbxsphN3xLFctEmtGKaVpQawaWWimvNucyF5mZSGMK4NIpnQk0IkaBMVeVK51UKQKhgihbsHN0OtU3w3x3EttzaqKCupQPfxTLPUs54nu1lMkgVfIwBTNkEu5VhV1JS7mcuh5nLYebe3_w2d9UW9EH_7dqDuwH4rvm363qgm9j6cMCcpoxwLtgPCJCTYA</recordid><startdate>20110701</startdate><enddate>20110701</enddate><creator>Smith, Graegar</creator><creator>Michelson, Joshua</creator><creator>Singh, Rohit</creator><creator>Dabbagh, Alya</creator><creator>Hoekstra, Edward</creator><creator>van den Ent, Maya</creator><creator>Mallya, Apoorva</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20110701</creationdate><title>Is There Enough Vaccine to Eradicate Measles? An Integrated Analysis of Measles-Containing Vaccine Supply and Demand</title><author>Smith, Graegar ; Michelson, Joshua ; Singh, Rohit ; Dabbagh, Alya ; Hoekstra, Edward ; van den Ent, Maya ; Mallya, Apoorva</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c386t-1b3d1b11f64adac4dd44a86d4f59f034afc476c500aecfbb8cd8b2ee0163c193</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Child, Preschool</topic><topic>Countries</topic><topic>Developed Countries</topic><topic>Developing Countries</topic><topic>FEASIBILITY OF MEASLES ERADICATION</topic><topic>Financial risk</topic><topic>Forecasting</topic><topic>Global Health</topic><topic>Humans</topic><topic>Immunization</topic><topic>Infant</topic><topic>Measels mumps rubella vaccine</topic><topic>Measles</topic><topic>Measles - prevention & control</topic><topic>Measles Vaccine - economics</topic><topic>Measles Vaccine - supply & distribution</topic><topic>Measles vaccines</topic><topic>Political campaigns</topic><topic>Rubella</topic><topic>Supply</topic><topic>Vaccination</topic><topic>Vaccination - economics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Smith, Graegar</creatorcontrib><creatorcontrib>Michelson, Joshua</creatorcontrib><creatorcontrib>Singh, Rohit</creatorcontrib><creatorcontrib>Dabbagh, Alya</creatorcontrib><creatorcontrib>Hoekstra, Edward</creatorcontrib><creatorcontrib>van den Ent, Maya</creatorcontrib><creatorcontrib>Mallya, Apoorva</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Smith, Graegar</au><au>Michelson, Joshua</au><au>Singh, Rohit</au><au>Dabbagh, Alya</au><au>Hoekstra, Edward</au><au>van den Ent, Maya</au><au>Mallya, Apoorva</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Is There Enough Vaccine to Eradicate Measles? An Integrated Analysis of Measles-Containing Vaccine Supply and Demand</atitle><jtitle>The Journal of infectious diseases</jtitle><addtitle>J Infect Dis</addtitle><date>2011-07-01</date><risdate>2011</risdate><volume>204</volume><issue>suppl_1</issue><spage>S62</spage><epage>S70</epage><pages>S62-S70</pages><issn>0022-1899</issn><eissn>1537-6613</eissn><abstract>Responding to regional advancements in combating measles, the World Health Organization in May 2008 called for an assessment of the feasibility of measles eradication, including whether sufficient vaccine supply exists. Interviews with international health officials and vaccine-makers provided data for a detailed model of worldwide demand and supply for measles-containing vaccine (MCV). The study projected global MCV demand through 2025 with and without a global eradication goal. The study found that 5.2 billion MCV doses must be administered during 2010-2025 to maintain current measles programs, and 5.9 billion doses would likely be needed with a 2020 eradication goal; in the most intensive scenario, demand could increase to 7.5 billion doses. These volumes are within existing and planned MCV-manufacturing capacity, although there are risks. In some markets, capacity is concentrated: Supply-chain disruptions could reduce supply or increase prices. Mitigation strategies could include stockpiling, long-term contracts, and further coordination with manufacturers.</abstract><cop>United States</cop><pub>Oxford University Press</pub><pmid>21666215</pmid><doi>10.1093/infdis/jir130</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0022-1899 |
ispartof | The Journal of infectious diseases, 2011-07, Vol.204 (suppl_1), p.S62-S70 |
issn | 0022-1899 1537-6613 |
language | eng |
recordid | cdi_proquest_miscellaneous_872434879 |
source | JSTOR Archival Journals and Primary Sources Collection; Oxford Journals Online |
subjects | Child, Preschool Countries Developed Countries Developing Countries FEASIBILITY OF MEASLES ERADICATION Financial risk Forecasting Global Health Humans Immunization Infant Measels mumps rubella vaccine Measles Measles - prevention & control Measles Vaccine - economics Measles Vaccine - supply & distribution Measles vaccines Political campaigns Rubella Supply Vaccination Vaccination - economics |
title | Is There Enough Vaccine to Eradicate Measles? An Integrated Analysis of Measles-Containing Vaccine Supply and Demand |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T14%3A58%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Is%20There%20Enough%20Vaccine%20to%20Eradicate%20Measles?%20An%20Integrated%20Analysis%20of%20Measles-Containing%20Vaccine%20Supply%20and%20Demand&rft.jtitle=The%20Journal%20of%20infectious%20diseases&rft.au=Smith,%20Graegar&rft.date=2011-07-01&rft.volume=204&rft.issue=suppl_1&rft.spage=S62&rft.epage=S70&rft.pages=S62-S70&rft.issn=0022-1899&rft.eissn=1537-6613&rft_id=info:doi/10.1093/infdis/jir130&rft_dat=%3Cjstor_proqu%3E41230446%3C/jstor_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c386t-1b3d1b11f64adac4dd44a86d4f59f034afc476c500aecfbb8cd8b2ee0163c193%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=872434879&rft_id=info:pmid/21666215&rft_jstor_id=41230446&rft_oup_id=10.1093/infdis/jir130&rfr_iscdi=true |